BPC
VKTX icon

Bryce Point Capital’s Viking Therapeutics VKTX Stock Holding History

Bryce Point Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$305K Sell
11,612
-7,228
-38% -$216K 0.37% 143
2025
Q2 		$499K Buy
+18,840
New +$496K 0.42% 141

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bryce Point Capital's VKTX Position: Q3 2025 in Review

Bryce Point Capital reduced its Viking Therapeutics (VKTX) stake by 38% in Q3 2025, selling an estimated $216K and leaving 11,612 shares worth $305K. The position accounts for 0.37% of the portfolio, ranked #143.

Bryce Point Capital first reported a position in VKTX in Q2 2025 and has held it in 2 quarters since. The position peaked at $499K in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Bryce Point Capital held 11,612 shares of Viking Therapeutics worth $305K as of Q3 2025.
  • Bryce Point Capital sold 7,228 Viking Therapeutics shares in Q3 2025, an estimated $216K.
  • Viking Therapeutics made up 0.37% of Bryce Point Capital's portfolio in Q3 2025, its #143 holding.
  • Bryce Point Capital first reported a position in Viking Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Bryce Point Capital's Viking Therapeutics position peaked at $499K in Q2 2025.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.